Trek Financial LLC Purchases 4,971 Shares of Thermo Fisher Scientific Inc. $TMO

Trek Financial LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 4,971 shares of the medical research company’s stock, valued at approximately $3,356,000.

A number of other hedge funds have also recently modified their holdings of the company. Bank OZK purchased a new position in Thermo Fisher Scientific in the second quarter worth approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the second quarter worth $456,000. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. German American Bancorp Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter valued at $4,920,000. Finally, Parallax Volatility Advisers L.P. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $814,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Argus increased their price target on Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a report on Friday. DZ Bank downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. BMO Capital Markets cut shares of Thermo Fisher Scientific to a “market perform” rating in a research report on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $689.10.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 275 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the transaction, the vice president owned 11,560 shares of the company’s stock, valued at $8,166,562. This trade represents a 19.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 76,199 shares of company stock valued at $45,896,780. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 2.1%

Thermo Fisher Scientific stock opened at $682.43 on Tuesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $711.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a 50 day moving average price of $655.94 and a 200 day moving average price of $553.32. The company has a market capitalization of $252.33 billion, a PE ratio of 35.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period in the prior year, the firm earned $5.79 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.